BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28031206)

  • 1. Physiological Differences in Cryptococcus neoformans Strains
    Grossman NT; Casadevall A
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031206
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B.
    Carlson T; Lupinacci E; Moseley K; Chandrasekaran S
    FEMS Microbiol Lett; 2021 May; 368(7):. PubMed ID: 33877319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.
    Mdodo R; Moser SA; Jaoko W; Baddley J; Pappas P; Kempf MC; Aban I; Odera S; Jolly P
    Mycoses; 2011 Sep; 54(5):e438-42. PubMed ID: 21535451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
    Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
    J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
    Casadevall A; Spitzer ED; Webb D; Rinaldi MG
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1383-6. PubMed ID: 8328793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relationship between drug susceptibility of Cryptococcus neoformans isolates and mortality in HIV-negative cryptococcal meningitis.
    Su Z; Wei H; Liu J; Li C; Xu Z; Yuan D; Dai K; Peng F; Jiang Y
    J Glob Antimicrob Resist; 2024 Mar; 36():167-174. PubMed ID: 38141953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.
    van Duin D; Casadevall A; Nosanchuk JD
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3394-400. PubMed ID: 12384341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
    Chayakulkeeree M; Tangkoskul T; Waywa D; Tiengrim S; Pati N; Thamlikitkul V
    J Mycol Med; 2020 Apr; 30(1):100905. PubMed ID: 31706700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of melanin upon susceptibility of Cryptococcus to antifungals.
    Ikeda R; Sugita T; Jacobson ES; Shinoda T
    Microbiol Immunol; 2003; 47(4):271-7. PubMed ID: 12801064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.